- Home
- TXRH vs SRPT Comparison
TXRH vs SRPT Comparison
Compare TXRH & SRPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TXRH
- SRPT
- Stock Information
- Founded
- TXRH 1993
- SRPT 1980
- Country
- TXRH United States
- SRPT United States
- Employees
- TXRH N/A
- SRPT N/A
- Industry
- TXRH Restaurants
- SRPT Biotechnology: Pharmaceutical Preparations
- Sector
- TXRH Consumer Discretionary
- SRPT Health Care
- Exchange
- TXRH Nasdaq
- SRPT Nasdaq
- Market Cap
- TXRH 11.2B
- SRPT 9.8B
- IPO Year
- TXRH 2004
- SRPT 1997
- Fundamental
- Price
- TXRH $166.63
- SRPT $63.82
- Analyst Decision
- TXRH Buy
- SRPT Buy
- Analyst Count
- TXRH 24
- SRPT 21
- Target Price
- TXRH $192.13
- SRPT $160.52
- AVG Volume (30 Days)
- TXRH 1.1M
- SRPT 2.3M
- Earning Date
- TXRH 05-01-2025
- SRPT 04-30-2025
- Dividend Yield
- TXRH 1.63%
- SRPT N/A
- EPS Growth
- TXRH 42.51
- SRPT N/A
- EPS
- TXRH 6.47
- SRPT 2.34
- Revenue
- TXRH $5,373,332,000.00
- SRPT $1,901,979,000.00
- Revenue This Year
- TXRH $10.79
- SRPT $69.30
- Revenue Next Year
- TXRH $8.80
- SRPT $22.64
- P/E Ratio
- TXRH $25.75
- SRPT $27.29
- Revenue Growth
- TXRH 16.01
- SRPT 52.97
- 52 Week Low
- TXRH $146.75
- SRPT $62.50
- 52 Week High
- TXRH $206.04
- SRPT $173.25
- Technical
- Relative Strength Index (RSI)
- TXRH 39.31
- SRPT 23.73
- Support Level
- TXRH $167.88
- SRPT $70.91
- Resistance Level
- TXRH $179.59
- SRPT $76.67
- Average True Range (ATR)
- TXRH 4.64
- SRPT 4.23
- MACD
- TXRH -0.27
- SRPT -1.68
- Stochastic Oscillator
- TXRH 20.34
- SRPT 3.23
About TXRH Texas Roadhouse Inc.
Texas Roadhouse Inc is a restaurant company operating predominately in the casual dining segment. The company's operating segment includes Texas Roadhouse; Bubba's 33 and others. It generates maximum revenue from the Texas Roadhouse segment.
About SRPT Sarepta Therapeutics Inc. (DE)
Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Majority of company's product candidates are at an early stage of development.